V508 Assessment: renal bone disease
Written V0508 on the CMS-2567 and in QCOR.
Cited on this tag? What happens after a citation · One-page sheet for the binder
The regulation
§ 494.80(a) Standard: Assessment criteria. The patient’s comprehensive assessment must include, but is not limited to, the following: (5) Evaluation of factors associated with renal bone disease.
CMS's interpretive guidance
Interpretive Guidance §494.80(a)(5)
Disturbances in mineral and bone metabolism are common in patients with ESRD, often resulting in hyperparathyroidism and Chronic Kidney Disease (CKD) mineral and bone disorder if not managed effectively.
Evaluation should include the patient’s laboratory values for calcium, phosphorous, and parathyroid hormone (PTH), along with a review of the patient’s current CKD mineral and bone disorder medications (e.g. phosphate binders, vitamin D analogs, calcimimetic agents), over-the-counter medications, dietary factors, and medical conditions that may impact this issue.
Pediatric patients present significant special needs in the areas of growth and development and CKD mineral and bone disorder. A facility treating pediatric patients should follow current professionally-accepted clinical practice standards for evaluating and monitoring the pediatric patient population in this area.
Citation should not be based solely on the patient’s clinical laboratory results for disturbances in mineral and bone metabolism, e.g. phosphorus and calcium levels. Any deficiency for mineral and bone metabolism management must be supported by the facility’s lack of identification and assessment of the patient’s metabolic status and/or failure to develop or implement an appropriate plan to help meet the patient’s needs.
Requirements for the plan of care for CKD mineral and bone disorder management are at V546.
Connected tags
Tags whose guidance points here
https://middlemolecule.com/rulebook/tags/v508/